Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1074 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-02-04
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 35.41 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 65.00 | Oscillator | Neutral |
| Williams %R (14) | -35.00 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.02 (Hist 0.01) | Oscillator | Buy |
| Average Directional Index (14) | 28.50 (+DI 20.4 / -DI 25.0) | Trend | Strong Sell |
Current price $0.103
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| EMA 20 | 0.11 | MA | Strong Sell |
| SMA 20 | 0.10 | MA | Buy |
| EMA 50 | 0.21 | MA | Strong Sell |
| SMA 50 | 0.14 | MA | Strong Sell |
| SMA 200 | 0.46 | MA | Strong Sell |
| Dec 3, 25 |
| Leerink Partners |
| downgrade |
| Outperform |
| Market Perform |
| May 14, 25 | RBC Capital | maintain | Sector Perform | Sector Perform |
| Dec 23, 24 | William Blair | downgrade | Outperform | Market Perform |
| Dec 20, 24 | RBC Capital | maintain | Sector Perform | Sector Perform |
| Dec 2, 24 | UBS | downgrade | Buy | Neutral |
| Nov 29, 24 | RBC Capital | downgrade | Outperform | Sector Perform |
| Nov 29, 24 | Citigroup | maintain | Buy | Buy |
| Nov 29, 24 | Baird | maintain | Outperform | Outperform |
| Nov 27, 24 | Citigroup | maintain | Buy | Buy |
FY2024 · 10-K disclosure
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Feb 3, 26 | Kanter Stacy J. | director | D-Return | 22,500 @ $0.088 | $1.98K |
| Feb 3, 26 | Kanter Stacy J. | director | D-Return | 200,000 @ $0.395 | $79.00K |
| Feb 3, 26 | Kanter Stacy J. | director | U-Tender | 42,500 @ $0.088 | $3.74K |
| Feb 3, 26 | Kanter Stacy J. | director | D-Return | 16,500 @ $1.05 | $17.32K |
| Dec 19, 25 | Hooks Corwin Dale | officer: Chief Commercial Officer | A-Award | 312,500 | — |
| Feb 3, 26 | Hooks Corwin Dale | officer: Chief Commercial Officer | D-Return | 862,500 @ $0.088 | $75.90K |
| Feb 3, 26 | Hooks Corwin Dale | officer: Chief Commercial Officer | U-Tender | 5,753 | — |
| Dec 19, 25 | Chinoporos Constantine | officer: See Remarks | A-Award | 437,500 | — |
TTM vs. 5-year historical average (annual ratios)
| Metric | APLT | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.4x | -2.2x · sector 20.7x | Discount |
| Forward P/E (FY25E) | -0.2x | EPS est. -0.53 | Discount |
| Price / Book | -26.7x | 0.5x | Discount |
| Price / Sales | 14.9x | 58.2x | Discount |
| EV / EBITDA | -0.1x | -1.8x | Discount |
| Return on equity | -477.8% | — | Weak |
| Gross margin | -892.3% | -2210.5% | Below hist. |
| Debt / Equity | -4.46 | 0.11 | Conservative |
| Piotroski / Altman Z | 1/9 | Z -27.42 | Distress |
Discounted cash flow model
Stock news · updated daily
Q32 Bio (NASDAQ: QTTB - Get Free Report) and Applied Therapeutics (NASDAQ: APLT - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation. Institutional and Insider Ownership 31.3% of Q32
Applied Therapeutics (NASDAQ: APLT - Get Free Report) and Immuron (NASDAQ: IMRN - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk. Analyst Recommendations This is a breakdown of recent
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Nov 13, 2025 | -0.14 | -0.13 | Beat 7.8% | $1.00M |
| Aug 13, 2025 | -0.17 | -0.15 | Beat 9.1% | — |
| May 13, 2025 | -0.18 | -0.15 | Beat 17.8% | — |
| Apr 14, 2025 | -0.18 | 0.52 | Beat 384.2% | -$1.00K |
| Nov 7, 2024 | -0.16 | -0.48 | Miss -203.9% | $122.0K |
| Aug 7, 2024 | -0.16 | -0.13 | Beat 21.1% | $144.0K |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| SC 13G/A | Feb 17, 2026 | 2026-02-17 16:08:56 | View |
| 15-12G | Feb 13, 2026 | 2026-02-13 08:30:17 | View |
| EFFECT | Feb 6, 2026 | 2026-02-09 00:15:13 | View |
| EFFECT | Feb 6, 2026 | 2026-02-09 00:15:09 | View |
| 4 | Feb 4, 2026 | 2026-02-04 11:17:54 | View |
| 4 | Feb 3, 2026 | 2026-02-03 19:16:05 | View |
| 4 | Feb 3, 2026 | 2026-02-03 19:03:25 | View |
| 4 | Feb 3, 2026 | 2026-02-03 18:50:35 | View |
| 4 | Feb 3, 2026 | 2026-02-03 18:47:47 | View |
| 4 | Feb 3, 2026 | 2026-02-03 18:46:19 | View |
Proxy statement (DEF 14A) disclosures